The enrolled patients were divided into four cohorts including ER+/PR+, ER+/PR-, ER-/PR+ and ER-/PR- according to HoR status. Then, Pearson’s χ2 test was used to estimate the clinicopathologic difference among these four cohorts. The cancer-specific survival (CSS) and overall survival (OS) were the endpoints of our study. CSS was defined as the interval from the diagnosis of breast cancer to death caused by breast cancer or the final follow-up in censored cases, and OS was defined as the interval from diagnosis of breast cancer to death from all causes or the last follow-up in censored cases. Survival differences were assessed through Kaplan-Meier analysis, followed by a log−rank test. Then, the multivariable Cox proportional hazards model was used and hazard ratios (HR) with the corresponding 95% confidence intervals (CI) were subsequently calculated to estimate the independent prognostic factors. STATA software (Version 13; Stata Corporation) was applied for all statistical analyses. The forest plot was generated by Microsoft Office Excel (Version 2021; Microsoft Corporation). All tests were two sided and p value <0.05 were considered statistically significant.
Free full text: Click here